retatrutide triple agonist obesity trial ⭐️topline results from TRIUMPH-1, a Phase 3 clinical evaluating #retatrutide, an investigational GIP / GLP-1 / glucagon hormone receptor agonist, in adults with or “overweight” Lilly's triple agonist, retatrutide, successful

According to the company's own published disclosures, these medications are "produced in FDA-regulated facilities" but are "not FDA-approved or evaluated for safety, efficacy, or quality." FDA-approved branded Ozempic is also listed on the platform at a higher price point

Find your recommended protein intake Calculate your recommended daily protein needs for weight loss, maintaining weight, or building muscle, based on your current weight and activity level

Since enzymes quickly break down natural GLP-1, GLP-1 RA drugs extend the effects of the natural hormone

Global burden of metabolic dysfunction-associated steatotic liver disease